γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen presentation, which makes them a highly promising effector cell compartment for cancer immunotherapy. Novel γδ T-cell-based immunotherapies, primarily focusing on the two major γδ T-cell subtypes that infiltrate tumors (i.e. Vδ1 and Vδ2), are being developed. The Vδ1 T-cell subset is enriched in tissues and contains both effector T-cells as well as regulatory T-cells with tumor-promoting potential. Vδ2 T-cells, in contrast, are enriched in circulation and consist of a large, relatively homogeneous, pro-inflammatory effector T-cell subset. Healthy individuals typically harbor in the order of 50-500 million Vγ9Vδ2 T-cells in the peripheral blood alone (1-10% of the total CD3+ T-cell population), which can rapidly expand upon stimulation. The Vγ9Vδ2 T-cell receptor senses intracellular phosphorylated metabolites, which accumulate in cancer cells as a result of mevalonate pathway dysregulation or upon pharmaceutical intervention. Early clinical studies investigating the therapeutic potential of Vγ9Vδ2 T-cells were based on either ex vivo expansion and adoptive transfer or their systemic activation with aminobisphosphonates or synthetic phosphoantigens, either alone or combined with low dose IL-2. Immune-related adverse events (irAE) were generally mild, but the clinical efficacy of these approaches provided overall limited benefit. In recent years, critical advances have renewed the excitement for the potential of Vγ9Vδ2 T-cells in cancer immunotherapy. Here, we review γδ T-cell-based therapeutic strategies and discuss the prospects of those currently evaluated in clinical studies in cancer patients as well as future therapies that might arise from current promising pre-clinical results.

Keywords: gamma delta T-cell, cancer, immunotherapy, phosphoantigens, aminobisphosphonates, adoptive cell transfer, bispecific t-cell engager, chimeric antigen receptor

INTRODUCTION

In humans, γδ T-cells represent 1 to 10% of total CD3+ T-cells (1, 2), and express a combination of either of 7 different Vγ TCR chains (Vγ2, 3, 4, 5, 8, 9, and 11), paired with either of 4 Vδ (Vδ1, 2, 3, and 5) chains (2–4). γδ T-cells are considered to bridge the innate and adaptive immune systems (3). Activated γδ T-cells display strong cytotoxic activity through the release of granzyme B and perforin, by membrane bound TRAIL and Fas (CD95) ligands or production of IFNγ or TNFα to
amplify the immune response (12), thereby counteracting tumor development. Using γδ T-cell-deficient mice in a cutaneous carcinogenesis model, γδ T-cells were first shown to prevent malignancy formation (5). High γδ T-cell frequency in tumor infiltrates from cancer patients correlates with better clinical outcome in different malignancies (6–10) and γδ T-cells were identified as the prognostically most favorable immune cell subset in tumor infiltrates from 18,000 tumors across 39 malignancies (11). A more recent study confirmed the relative abundance of Vγ9Vδ2 T-cells in TILs and their association with improved patient outcome (12). These results highlight the relevance of γδ T-cells in tumor control and their potential for cancer therapy. γδ T-cells express several receptors shared with natural killer (NK) cells that participate in enhanced tumor cell recognition of which FcγRIIIa (CD16a), DNAM-1, and NKG2D are a few examples (13) (Figure 1A).

**FIGURE 1** | (A) Key characteristics of the two main γδ T-cell subsets, Vδ2 and Vδ1 T-cells, in cancer biology. (B) Schematic representation of therapeutic strategies involving γδ T-cells that are currently being developed. ADCC, Antibody-dependent cellular cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; bsAb, bispecific antibody; bsVHH, bispecific variable domain of heavy-chain only antibody; BTN, Butyrophilin; CAR, chimeric antigen receptor; pAg, phosphoantigen; scFv, single-chain variable fragment.
The complete repertoire of antigens recognized by γδ TCRs and the specificity of each γδ T subset is still not fully understood. Vγ9Vδ2 T-cells represent the predominant γδ T-cell subset (95%) in peripheral blood (14). Vγ9Vδ2 T-cells participate in the defense against malignant cells by sensing small phosphorylated metabolites (phosphoantigen (pAg) molecules) produced in cholesterol synthesis [isopentenyl pyrophosphate (IPP)] or by pathogens [e.g. (E)-4-hydroxy-3-methyl-2-enyl-pyrophosphate (HMBPP)] (5, 15–19). Unlike conventional αβ T-cells, ligand recognition by Vγ9Vδ2 and most γδ T-cells does not involve antigen presentation by human leukocyte antigen (HLA) molecules (15, 20). Ligand recognition by Vγ9Vδ2 T-cells requires butyrophilin (BTN) 3A1 (21) and BTN2A1 (22–24). Intracellular pAg levels are increased under stress conditions like infection or malignant transformation or by aminobisphosphonates (ABP) (16, 17, 25–27). Vγ9Vδ2 T-cells sense increased intracellular pAg levels causing their activation and target cell killing. Recent studies show that pAg-bound BTN3A1 associates with BTN2A1 which directly interacts with non-variable regions of the Vγ9 chain on γδ T-cells. Besides Vγ9Vδ2 T-cell recognition of pAgs, some subsets of Vδ1 and Vδ3 T-cells detect pathogenic and self-lipids presented by CD1d through their TCR (28, 29). Vδ1 T-cells are less abundant in circulation than Vγ9Vδ2 T-cells, but they are enriched in epithelia (30) and among tumor infiltrating lymphocytes (TILs). While cultured Vδ1 T-cells may have higher cytotoxic capacity than Vγ9Vδ2 T-cells, Vδ1 T-cells can be pro-tumoral in certain malignancies (6, 31, 32) (Figure 1A).

In this review we discuss γδ T-cell-based therapeutic strategies with a focus on recent developments of bispecific γδ T-cell engagers (bsTCES) and chimeric antigen receptor (CAR) γδ T-cells, and point towards approaches that may develop into therapies in the near future (Figure 1B).

**PAST CLINICAL STUDIES WITH Vγ9Vδ2 T-CELLS**

In the year 2000, ABP drugs, already approved to treat patients with excessive bone resorption, were shown to cause systemic Vγ9Vδ2 T-cell stimulation and to increase their antitumor activity in a preclinical study (26). Following this observation, studies explored ABP treatment as a systemic γδ T-cell stimulant or as an ex vivo tool to expand them for subsequent adoptive cell transfer (ACT) for cancer immunotherapy.

The ABPs pamidronate (PAM) and zoledronate (ZOL), and synthetic pAg analogues, mainly bromohydrin pyrophosphate (BrHPP) and 2-methyl-3-buteryl-1-pyrophosphate (2M3B1PP), have been used alone or in combination with IL-2 to activate Vγ9Vδ2 T-cells (33, 34). ABP treatment has been evaluated in cancer patients (e.g. with multiple myeloma (MM), non-Hodgkin lymphoma (NHL), acute myeloid leukemia (AML), prostate cancer, renal cell carcinoma, colorectal cancer, breast cancer, melanoma, or neuroblastoma) (33, 35–39). Additionally, ex vivo expansion of autologous γδ T-cells with ABPs or synthetic pAg followed by ACT has been tested in a wide range of malignancies (e.g. in MM, renal cell carcinoma, non-small cell lung cancer, gastric cancer, hepatocellular carcinoma, melanoma, ovarian cancer, colon cancer and pancreatic cancer) (40–51). While these approaches were well tolerated, clinical responses typically were found to be infrequent and not long-lasting, though sporadic meaningful responses were achieved (52–54). The overall moderate clinical antitumor effect of systemic γδ T-cell activation with ABP or synthetic pAg and of autologous γδ T transfer, negatively impacted further development of these Vγ9Vδ2 T-cell-directed cancer immunotherapeutic approaches.

**PRESENT AND FUTURE STUDIES INVOLVING γδ T-CELLS**

### γδ T-Cell-Based Cellular Strategies

#### Allogeneic γδ T-Cell Transfer

As mentioned above, most γδ T-cells recognize target cells independently of HLA antigen presentation, suggesting that allogeneic donor derived γδ T-cells can be relatively safe for ACT due to low risk of graft-versus-host disease (GvHD). Taking advantage of this, current strategies exploring the use of ex vivo expanded γδ T-cell infusion have shifted towards allogeneic origin (Table 1). Increased frequency of γδ T-cells in leukemia patients that underwent αβ-depleted allogeneic stem cell transplantation from partially HLA-mismatched donors, was associated with a higher 5-year and overall survival (OS) (55, 56). A single infusion of allogeneic Vγ9Vδ2 T-cells, expanded ex vivo with ZOL plus IL-2, is being administered in a clinical trial (NCT03533816) to maximize antitumor response and reduce GvHD, after allogeneic hematopoietic cell transplant (alloHCT) and cyclophosphamide for hematologic malignancies. Moreover, allogeneic Vγ9Vδ2 T-cell infusion after lymphodepletion is being tested independently of alloHCT for hematologic malignancies and solid tumors. Some of these studies have already been completed with no major adverse effects reported, highlighting the safety of Vγ9Vδ2 T-cell transfer (57, 58). Importantly, patients receiving Vγ9Vδ2 T-cell infusion had increased OS compared to control patients and repeated Vγ9Vδ2 T-cell infusions resulted in higher OS when compared to single infusion. Future approaches are based on allogeneic γδ T-cells derived from healthy donors, either unmodified or CAR-transfected (see below) (Table 2).

Application of non-Vγ9Vδ2 T-cell subsets, like Vδ1 T-cells, is of interest but lagged behind because of lack of proper expansion protocols. In 2016, Almeida et al. described a 3 week culture protocol based on stimulation of γδ T-cells from healthy donors or CLL patients with a combination of cytokines and anti-CD3 monoclonal antibody (mAb) clone OKT-3, resulting in 2000-fold expansion and 60-80% enrichment of Vδ1 T-cells (59). Expanded cells expressed the NK receptors Nkp30 and Nkp40, displayed cytotoxic activity, produced IFNγ, TNFα and no IL-17. Application of this protocol led to the development of different “delta one T” (DOT) cell products. Gamma Delta Therapeutics initiated a first-in-human phase I clinical trial in AML patients after lymphodepletion with fludarabine and cyclophosphamide (NCT05001451) (Table 1). This study will analyse safety and
### TABLE 1 | Ongoing clinical trials based on γδ T-cells.

| Title                                                                 | Intervention                                                                 | Malignancy                                                                 | Organization                                                                 | Phase | Initial Date | Status       | Study Identifier |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------|-------|--------------|--------------|------------------|
| **Allogeneic γδ T-cell transfer**                                     | HPC-A Infusion (TORαβ and CD19+ depleted)                                     | ALL, AML, MDS, NK-CL, Hu., NHL., JMML,CML                                | St. Jude Children’s Research Hospital                                        | II    | January 31, 2019 | Recruiting    | NCT03849651     |
| Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia | Ex-vivo expanded allogeneic γδ T-cells from blood of related donors         | AML                                                                       | Wuhan Union Hospital and Jinan University, China                             | I     | September 1, 2019 | Recruiting    | NCT04008381     |
| Expanded/Activated Gamma Delta T-cell infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide | EAGD T-cell infusion                                                       | AML, CML, ALL, MDS                                                        | University of Kansas Medical Center and Inhibio Inc.                         | I     | January 31, 2020 | Recruiting    | NCT03533816     |
| Allogeneic “Gammadelta T Cells (γδ T Cells)” Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial | Ex-vivo expanded allogeneic γδ T-cells from related donors                  | HCC                                                                       | Beijing 302 Hospital                                                         | I     | August 15, 2020  | Recruiting    | NCT04518774     |
| Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT | AllotHCT + AAPC-expanded donor T-cells                                    | AML                                                                       | H. Lee Moffitt Cancer Center and Research Institute                         | I/II  | August 13, 2021  | Recruiting    | NCT05015426     |
| Study of GDX012 in Patients With MRD Positive AML                    | GDX012. Allogeneic cell therapy enriched for Vδ1+                          | AML                                                                       | GammaDelta Therapeutics Limited                                               | I     | August 13, 2021  | Recruiting    | NCT05001451     |
| Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin’s Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients | Ex-vivo expanded allogeneic γδ T-cells from related donors                  | NHL, PTCL                                                                 | Institute of Hematology & Blood Diseases Hospital                            | I     | January 6, 2021  | Recruiting    | NCT04696705     |
| Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT | Ex-vivo expanded γδ T-cell infusion                                       | AML, ALL, MDS                                                             | Chinese PLA General Hospital                                                 | II/I  | September 2021   | Recruiting    | NCT04784513     |
| Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL | Allogeneic γδ CAR-T-cells (anti-Cd19)                                      | RR, ALL, CLL, B-NHL                                                       | Beijing Doing Biomedical Co., Ltd.                                            | I     | October 2017      | Active, not recruiting | NCT02656147     |
| Haplo/Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | Haploidential or allogeneic Vδ2 CAR-T-cells (anti-NKG2DL) (CTM-N2D)         | RR solid tumors of different types                                        | CytoMed Therapeutics Pte Ltd.                                               | I     | December 1, 2019  | Active, not recruiting | NCT04107142     |
| A Study of ADI-001 in B Cell Malignancies (GLEAN-1)                  | Lymphodepletion + ADI-001 (Anti-Cd20 γδ CAR-T-cells) in monotherapy and combined with IL-2 | B-NHL                                                                     | Adicet Bio, Inc.                                                             | I     | March 4, 2021      | Recruiting    | NCT04735471     |
| First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICT) | ICT01 monoclonal antibody targeting BTN3A                                    | Solid Tumor, Adult Hematopoietic/Lymphoid Cancer                           | ImCheck Therapeutics                                                         | I/Ii  | February 10, 2020 | Recruiting    | NCT04243499     |
| Trial With LAVA-051 in Patients With Relapsed/Refractory CD1d (Cluster of Differentiation (CD)1d)-Positive CLL, MM, AML | LAVA-051, Bispecific γδ T-cell engager                                     | LAVA-051, Bispecific γδ T-cell engager                                    | Lava Therapeutics                                                           | I/Ii  | July 12, 2021     | Recruiting    | NCT04887259     |
| Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer | LAVA-1207, Bispecific γδ T-cell engager                                    | Prostate Cancer                                                           | Lava Therapeutics                                                           | I/Ii  | January 31, 2022   | Recruiting    | NCT05369000     |

(Continued)
maximum tolerated dose of GDX012 and its effect on minimal residual disease, progression free survival (PFS) and OS.

**Chimeric Antigen Receptor γδ T-Cells**

Another therapeutic approach to harness the potent anti-tumor effects of γδ T-cells consists of adoptive transfer of γδ CAR-T-cells (60). CARs are chimeric antigen-recognition receptors, consisting of an ectodomain, which binds a tumor specific cell surface receptor, and endodomains, consisting of CD3ζ as the signaling domain with co-stimulatory domains to provide robust activation (e.g. CD28, 4-1BB, or ICOS) (61). In recent years, CAR-T-cell therapy has been extensively investigated in preclinical and clinical studies, primarily focused on conventional αβ T-cells (62–64). These autologous CAR-T-cells have triggered encouraging remission rates in patients refractory to standard treatments against, in particular, B-lymphoid malignancies. This resulted in FDA approvals of CAR-T-cell therapies for the treatment of B-cell NHL, ALL,

### TABLE 1 | Continued

| Title | Intervention | Malignancy | Organization | Phase | Initial Date | Status | Study Identifier |
|-------|--------------|------------|--------------|-------|--------------|--------|-----------------|
| Safety of TEG001 in patients with r/r AML, high-risk MDS or MM | TEG001 | RR AML, high-risk MDS, MM | Gadeta B.V. | I | June 01, 2017 | Recruiting | NTR6541 |
| Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma | DRI γδ T-cells modified to be resistant to TMZ + TMZ | Glioblastoma multiforme | University of Alabama at Birmingham and IN8Bio Inc. | I | February 11, 2020 | Recruiting | NCT04165941 |
| A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients | TEG002 | RR MM | Gadeta B.V. | I | May 13, 2021 | Recruiting | NCT04688853 |

### TABLE 2 | Companies developing γδ T-cell-based or γδ T-cell-engaging therapies.

| Organization | γδ T-cell subtype | Approach |
|--------------|-------------------|----------|
| Acepodia | information not available | Allogeneic mAb-conjugated γδ-cells |
| Adicet Bio | Vδ1 | Allogeneic γδ CAR-T-cells |
| Expression Therapeutics | Vδ2 | Allogeneic γδ CAR-T-cells |
| GammaDelta Therapeutics (acquired by Takeda) | Vδ1 | Allogeneic unmodified or engineered Vδ1+ T-cells |
| Immatics | information not available | Allogeneic γδ CAR-T-cells |
| IN8Bio (previously Incysus Therapeutics) | Vδ2 | Expanded γδ T-cells engineered to achieve drug resistant immunotherapy (DRI) |
| Kiroma Biopharma | information not available | Allogeneic γδ CAR-T-cells genetically engineered using ABBIE non-viral gene editing technology |
| PersonGen BioTherapeutics | information not available | Allogeneic universal CAR (UCAR) based γδ-cells |
| TC BioPharm | Vδ1/Vδ2 | Allogeneic unmodified γδ-cells or engineered γδ CAR-T-cells |
| One Chain Immunotherapeutics | Vδ1 | Expanded allogeneic Vδ1+ T-cells for ACT |
| Beroni group | information not available | Allogeneic γδ ACT |

| Organization | γδ T-cell subtype | Approach |
|--------------|-------------------|----------|
| Adaptate Biotherapeutics (acquired by Takeda) | Vδ1 | Vδ1 bispecific T-cell engagers |
| ImmCheck Therapeutics | Vδ2 | mAbs targeting BTN isoforms to modulate γδ T-cell activation |
| LAVA Therapeutics | Vδ2 | Vδ2 bispecific T-cell engagers |
| PureTech Health | Vδ1 | mAb against Vδ1 to induce pro-tumoral Vδ1 T-cell killing |
| Shattuck Labs | Vδ2 | Recombinant proteins containing heterodimeric BTN extracellular domains and a tumor targeting scFv |

**Other γδ T-cell-based therapies**

| Organization | γδ-T cell subtype | Approach |
|--------------|-------------------|----------|
| American Gene Technologies | Vδ2 | Lentivirus to increase pAg levels in tumor cells |

**ACT:** Adaptive cell transfer; bsTCE: bispecific T cell engager; bsVHH: bispecific Variable Heavy chain-only antibody; BTN: Butyrophilin; CAR: Chimeric antigen receptor; mAb, monoclonal antibody; pAg, phosphoantigen; scFv, Single chain variable fragment.
and MM (65–69). The remarkable success of CAR-T-cell therapy revolutionized the field of adoptive cell therapy for treating hematologic malignancies and resulted in numerous ongoing clinical trials. However, CAR-T-cell therapy can be complicated by severe, potentially life-threatening, toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and other ‘on-target off-tumor’ toxicities (70). Moreover, in contrast to the results seen in hematologic malignancies, only limited antitumor effects have been obtained in patients with solid tumors.

It was hypothesized that the efficacy of CAR-T-cells could be improved and its side effects mitigated by harnessing the innate properties of γδ T-cells as a backbone for CAR. CAR-modified γδ T-cells were first described by Rischer et al. (71), demonstrating specific in vitro tumor cell lysis using ZOL-expanded Vγ9Vδ2 T-cells with CD19- or GD2-directed CARs, followed by other studies confirming these findings using γδ T-cells containing CARs against a variety of targets (72–77). Interestingly, CAR-modified Vγ9Vδ2 T-cells maintained their ability to cross-present tumor antigens to ɑβ T-cells in vitro, which may prolong the anti-tumor efficacy (76). Furthermore, γδ T-cells bearing a CD19-CAR, unlike standard CD19-ɑβ CAR-T-cells, had reactivity against CD19-positive and negative tumor cells in vitro and in vivo, an effect that was enhanced by ZOL (78), suggesting that CD19-directed γδ CAR-T-cells may target leukemic cells also after antigen loss and retain pAg specificity via their TCR. More recently, Wallet et al. described the generation of induced pluripotent stem cell-derived γδ CAR-T-cells (γδ CAR-iT) (79). They demonstrated sustained in vitro tumor cell killing by γδ CAR-iT-cells in the presence of IL-15, with markedly less IFN-γ and other inflammatory cytokines being produced compared to conventional ɑβ CAR-T-cells, potentially resulting in lower risk of CRS. Moreover, a single dose of γδ CAR-iT-cells resulted in potent tumor growth inhibition in a xenograft mouse model (79). Table 2 summarizes the companies currently developing γδ CAR-T-cells.

Pre-clinical research on γδ CAR-T-cell based therapy initially focused on Vγ9Vδ2 T-cells, due to their dominant frequency in blood and their unique pAg response that allowed the specific expansion of this subset (80). Makkouk et al. recently showed the first example of genetically modified Vδ1 T-cells. They expanded PBMC-derived Vδ1 T-cells using an agonistic anti-Vδ1 antibody and genetically modified them to express a GPC-3 targeted CAR and to secrete IL-15 (81). In a HepG2 mouse model, these allogeneic Vδ1 CAR-T-cells primarily accumulated in the tumor and a single dose efficiently controlled tumor growth without evidence of xenogeneic GvHD. ADI-001 consists of CD20-targeting Vδ1 CAR-T-cells generated by a similar procedure by Adicet Bio (82) and is currently being used in a phase I clinical trial (NCT04735471). Recently reported interim data from this dose-escalation study showed complete responses in two and a partial response in one out of four evaluable patients already with low doses (30x10^6 cells) of ADI-001, indicating that relatively low amounts of γδ T-cells may suffice for activity (press release). To date, no dose-limiting toxicities, GvHD, or grade 3 or higher CRS has been reported. These encouraging first results underscore the potential of Vδ1 CAR-T-cell therapy in the clinic. A complete overview of the ongoing clinical trials evaluating CAR-modified γδ T-cells is listed in Table 1.

**Antibody-Based Strategies**

Imcheck develops ICT01, a Vγ9Vδ2 T-cell activating humanized IgG1 with a silent Fc that binds to all three BTN3A isoforms to trigger Vγ9Vδ2 T-cell activation and increased cytotoxicity against BTN3A+ tumor cell lines from diverse origin (21). However, this approach is not tumor specific as BTN3A is broadly expressed and could also be hampered by soluble BTN3A molecules potentially acting as decoy receptors (83). In immunodeficient NSG mice, treatment with ICT01 resulted in in vivo activation of adoptively transferred human Vγ9Vδ2 T-cells and delayed outgrowth of the AML cell line MOLM14 (84). The EVICTION trial is a Phase I/IIa clinical trial currently testing the effect of ICT01 in relapsed/refractory advanced-stage hematologic malignancies as a monotherapy and in a broad range of solid tumors as monotherapy or in combination with pembrolizumab (NCT04243499). Preliminary results show a good safety profile with activation of Vγ9Vδ2 T-cells and increased tumor infiltration in one melanoma patient. Stable disease has been achieved in 31% of patients treated with ICT01 as a monotherapy and in 62% in combination with pembrolizumab (84).

BsTCEs have emerged as a promising therapeutic approach for immune-oncology (85) and consist of a tumor antigen binding antibody linked to a T-cell engaging antibody fragment aiming to crosslink tumor cells and T-cells to elicit T-cell-mediated anti-tumor cytotoxicity (86, 87). Most efforts to generate bsTCEs have made use of CD3 as a T-cell engaging domain due to its role in T-cell activation. For CD3-based TCEs, proteins that are uniquely expressed or specifically overexpressed by tumor cells are the most attractive candidates for targeting, as this reduces on-target off-tumor toxicity. After approval of the CD19-CDS bsTCE blinatumomab (88), multiple CD3-directed TCEs have been developed (89), but in many cases development has been complicated by the occurrence of adverse events such as on-target off-tumor toxicity, CRS or ICANS, highlighting the need for more tumor-selective targeting (90–92). Considering the clinical safety observed following systemic γδ T-cell activation and γδ T ACT, specific engagement of γδ T-cells using γδ bsTCEs might have an improved safety profile due to their tumor selectivity compared to CD3-bsTCEs. By avoiding detrimental co-activation of regulatory CD3+ T-cells observed with CD3 pan T-cell engagers (93) and their ability to bridge and engage components of both the innate and adaptive immune system, γδ bsTCEs could potentially result in increased antitumor activity.

Several γδ T-cell engaging formats are being developed and evaluated preclinically. Vγ9-TCR specific engagers directed against Her2 (94–96) and CD123 (97) were shown to cause killing of Her2 expressing cell lines and AML cell lines, respectively. The GADLEN platform (Shattuck Labs) consists of fusion proteins containing BTN heterodimers, to engage and activate Vγ9Vδ2 T-cells, bound to a tumor targeting scFv.
domain through an Fc linker (98). Vδ1 bsTCEs are also being developed by Adaptate Biotherapeutics. Heavy chain only antibodies occur naturally in cameldids (99). Their antigen-binding fragments or variable heavy chain-only antibodies (VHH), are small, stable and with low inherent immunogenicity (100, 101). Lava Therapeutics’ Gambabody™ platform combines Vδ2-specific and tumor-targeting VHHs as modules to generate bsTCE (102–105). In pre-clinical studies, Gambabody™ molecules targeting CD40, CD1d and EGFR efficiently engage Vγ9Vδ2 T-cells to kill tumor cells expressing these antigens (102–105). Two Gambabody™ molecules, are currently evaluated in clinical trials. LAVA-051, a Gambabody™ targeting CD1d is tested in a Phase I/Ia clinical trial (NCT04887259) in patients with therapy-refractory CLL, AML or MM. Preliminary data of the first 3 cohorts from this study showed a thus far good safety profile with no dose-limiting toxicities or CRS. In addition, LAVA-1207, a Gambabody™ targeting PSMA is tested in a phase I/Ia clinical trial (NCT05369000) in patients suffering from therapy-refractory metastatic castration-resistant prostate cancer. Table 1 summarizes companies developing antibody-based γδ T-cell therapies, and Table 2 contains clinical trials involving antibody-based γδ T-cell approaches.

**Alternative γδ T-Cell-Related Strategies**

A new γδ T-cell based approach being tested in clinical trials is DeltEx drug-resistant immunotherapy (DRI). IN8Bio’s first DeltEx DRI product, INB-200, consists of expanded autologous Vγ9Vδ2 T-cells genetically modified to express a methylguanine DNA methyltransferase (MGMT). MGMT confers them resistance to temozolomide (TMZ) allowing for simultaneous treatment with TMZ and immunotherapy (106). TMZ, which is the current standard of care for glioblastoma multiforme (GBM) together with radiotherapy after resection, might sensitize tumor cells to γδ T-cell recognition through upregulation of NKG2D ligands but it also causes lymphocytopenia that is avoided by MGMT expression (107). An ongoing clinical trial (NCT04165941) is testing intracranial administration of INB-200 to the tumor site after surgical resection, followed by TMZ treatment (Table 1). All 4 GBM patients enrolled in this study have been reported to exceed the expected PFS for TMZ alone treatment. This technology is based on expansion and modification of autologous γδ T-cells, however, other DeltEx DRI based on allogeneic γδ T-cells (INB-400) and γδ CAR-T-cells (INB-300) are being developed.

Interestingly, although Vδ1+ T-cells have cytotoxic capacity, Vδ1+ TIL associate with poor prognosis in certain malignancies, possibly through production of IL-17 (6, 32). LYT-210 is a mAb directed towards the Vδ1+ TCR with the aim of eliminating these pathogenic cells (Table 2). Gamma-delta TCR bspecific molecules (GABs) combine the extracellular domain of the Vγ9Vδ2 TCR fused with a CD3 binding domain, allowing conventional T-cells to recognize the presence of pAg on tumor cells (108). In the presence of GABs, αβ T-cells recognized and killed the squamous cell carcinoma cell line SCC9 in a pAg dependent manner and produced increased amounts of IFNγ when exposed to patient-derived AML blasts but not with healthy hematopoietic cells indicating preferential recognition of tumor cells.

Two phase I dose-escalation clinical trials (NCT04688853; NTR6541) initiated by Gadeta are assessing the safety and tolerability of αβ T-cells engineered to express a defined Vγ9Vδ2 TCR (TEGs) in relapsed/refractory AML, MM, and high-risk myelodysplastic syndrome patients. These T-cells combine the tumor specificity of γδ T-cells with the tumor cell killing potential of αβ T-cells and show promising antitumor reactivity both in vitro and in vivo. Furthermore, chimeric PD-1 receptor (chPD1) γδ T-cells, turn PD-1 immune suppression into T-cell activation (109). The chPD1 γδ T-cells selectively killed PD-L1+ tumor cells in a xenograft murine model, without lysis of normal PD-L1+ cells or significant elevation of CRS-related cytokines. The authors reported that chPD1 γδ T-cell therapy will be assessed in a phase I/I clinical trial.

**CONCLUSION**

Past clinical trials have demonstrated that systemic activation of Vγ9Vδ2 T-cells or adoptive transfer of autologous Vγ9Vδ2 T-cells were well tolerated and could trigger antitumor immunity. These studies have been followed by a number of trials based on Vγ9Vδ2 and the first study with Vδ1 allogeneic T-cell transfer, which would allow for donor-derived therapies. Up to this date, these trials have not resulted in major adverse effects. Most strategies that are currently under evaluation profit from the safety of γδ T-cell activation and incorporate tumor-targeting mechanisms, e.g. CARs or bsTCEs, which might be key to obtain more robust and consistent clinical responses. Initial results from these targeted approaches, both cell and antibody-based, show great promise and confirm the safety of Vγ9Vδ2 and Vδ1 T-cell-based strategies. However, cell-based products present challenges that are not shared by antibody-based therapies, such as high cost, difficulty of production or need of specialized facilities, and preparatory lymphodepleting chemotherapy regimens. In the near future, the results obtained by the trials described in this review will determine whether the potential of γδ T-cells can be translated into clinical benefit.

**AUTHOR CONTRIBUTIONS**

JS-E and MJ wrote the manuscript. HV co-wrote and reviewed the manuscript. LK, PP, EE, BW and TG reviewed the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

The authors declare that this study received funding from LAVA therapeutics. The funder had the following involvement with the study: providing research funding to Amsterdam UMC and in designing, writing and revising the text of the mini-review.

---

**Table 1** Companies developing antibody-based γδ T-cell therapies.

| Company | Lead Candidate | Disease | Status |
|---------|----------------|---------|--------|
| Adaptate Biotherapeutics | Gambabody™ | CD40, CD1d, EGFR | Pre-clinical |
| LAVA Therapeutics | LAVA-051 | CD1d | Phase I/Ia |
| IN8Bio | INB-200 | Vγ9Vδ2 | Phase I/Ia |

**Table 2** Clinical trials involving antibody-based γδ T-cell approaches.

| Clinical Trial | Candidate | Target | Status |
|---------------|-----------|--------|--------|
| NCT04165941  | INB-200   | Vγ9Vδ2 | Ongoing |
| NCT05369000  | INB-200   | PSMA   | Ongoing |

---

**REFERENCES**

(98) Voirova, D., et al. 2022. Adaptate Biotherapeutics: advancing adoptive cell therapies for cancer. Front Immunol. 13:762090.

(100) D'Mello, A., et al. 2022. Progress in vaccine development for cancer immunotherapy. Front Immunol. 13:884856.

(101) Seethala, R., et al. 2020. S laid-back CML: the role of immunotherapy. Front Immunol. 11:120275.

---

(99) The authors declare that this study received funding from LAVA therapeutics. The funder had the following involvement with the study: providing research funding to Amsterdam UMC and in designing, writing and revising the text of the mini-review.
REFERENCES

1. Kozbor D, Trinchieri G, Monos DS, Isobe M, Russo G, Haney JA, et al. Human TCR-Gamma/Delta+, CD8+ T Lymphocytes Recognize Tenuate Toxoid in an MHC-Restricted Fashion. J Exp Med (1989) 169(5):1847–51. doi: 10.1084/jem.169.5.1847

2. Pistoia V, Tumino N, Vacca P, Veneziani I, Moretta A, Locatelli F, et al. Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias. Front Immunol (2018) 9:9884. doi: 10.3389/fimmu.2018.09884

3. Adams EJ, Gu S, Luoma AM. Human Gamma Delta T Cells: Evolution and Ligand Recognition. Cell Immunol (2015) 296(1):31–40. doi: 10.1016/j.cellimm.2015.04.008

4. Zhao Y, Niu C, Cui J. Gamma-Delta (Gammadelta) T Cells: Friend or Foe in Cancer Development? J Transl Med (2018) 16(1):3. doi: 10.1186/s12976-017-1378-2

5. Girardt M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al. Regulation of Cutaneous Malignancy by Gammadelta T Cells. Science (2001) 294(5542):605–9. doi: 10.1126/science.1063916

6. Meraviglia S, Lo Presti E, Tosolini M, La Mendola C, Orlando V, Todaro M, et al. Distinctive Features of Tumor-Infiltrating γδ T Lymphocytes in Human Coloarcctal Cancer. OncoImmunology (2017) 6(10):e1347742. doi: 10.1080/2162402X.2017.1347742

7. Wang J, Lin C, Li H, Li R, Wu Y, Liu H, et al. Tumor-Infiltrating γδ Cells Predict Prognosis and Adjuvant Chemotherapeutic Benefit in Patients With Gastric Cancer. OncoImmunology (2017) 6(11):e1355885. doi: 10.1080/2162402X.2017.1355885

8. Donia M, Elbeck E, Andersen MH, Straten PT, Svane IM. Analysis of Vδ1 T Cells in Clinical Grade Melanoma-Infiltrating Lymphocytes. OncoImmunology (2012) 1(8):1297–304. doi: 10.4161/onci.21659

9. Lu H, Dai W, Guo J, Wang D, Wen S, Yang L, et al. High Abundance of Intratumoral γδ T Cells Favor a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.573920

10. Zhao N, Dang H, Ma L, Martin SP, Gschwind RM, Kollas A-K, et al. Key Implication of CD277/butyrophilin-3 (BTN3A) in Cellular Stress Sensing by a Major Human γδ T-Cell Subset. Blood (2012) 120(11):2269–79. doi: 10.1182/blood-2012-05-430470

11. Harly C, Guillaume Y, Nedellec S, Pirinç CM, Mönkönen H, Mönkönen J, et al. Key Implication of CD277/butyrophilin-3 (BTN3A) in Cellular Stress Sensing by a Major Human γδ T-Cell Subset. Blood (2012) 120(11):2269–79. doi: 10.1182/blood-2012-05-430470

12. Gober HJ, Kistowska M, Angman L, Jenö P, Mori L, De Libero G. Human T Cell Receptor γδ Cells Recognize Endogenous Mevalonate Metabolites in Tumor Cells. J Exp Med (2003) 197(2):163–8. doi: 10.1084/jem.20021500

13. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of Gammadelta T Cells by Aminobisphosphonates and Induction of Antiplasma Cell Activity in Multiple Myeloma. Blood (2000) 96(2):384–92. doi: 10.1182/blood.v96.2.384

14. Dhar MK, Koul A, Kaul S. Farnesyl Pyrophosphate Synthase: A Key Enzyme in Isoprenoid Biosynthetic Pathway and Potential Molecular Target for Drug Development. N Biotechnol (2013) 30(2):114–23. doi: 10.1016/j.nbt.2012.07.001

15. Luoma AM, Castro CD, Mayassi L, Bai L, Picard D, et al. Crystal Structure of Vδ1 T Cell Receptor in Complex With CD1d-Sulfatide Shows MHC-Like Recognition of a Self-Lipid by Human γδ T Cells. Immunity (2013) 39(6):303–12. doi: 10.1016/j.immuni.2013.11.001

16. Mangan BA, Dunne MR, O’Reilly VP, Dunne PJ, Exley MA, O’Shea D, et al. Cutting Edge: CD1d Restriction and Th1/Th2/Th17 Cytokine Secretion by Human Vδ3 T Cells. J Immunol (2013) 191(1):30–4. doi: 10.4049/immunol.1300121

17. Deusch K, Pfeffer K, Reich C, Gatenbauer M, Daum S, Luling F, et al. Phenotypic and Functional Characterization of Human TCR Gamma Delta+ Intestinal Intraepithelial Lymphocytes. Curr Top Microbiol Immunol (1991) 173:279–83.

18. Wu D, Wu P, Wu X, Ye J, Wang Z, Zhao S, et al. Ex Vivo Expanded Human Circulating Vδ1gd T Cells Exhibit Favorable Therapeutic Potential for Colon Cancer. OncoImmunology (2015) 4(13):e992749. doi: 10.1080/2162402X.2014.992749

19. Li Y, Li G, Zhang J, Wu X, Chen X. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting. Front Immunol (2021) 11:619954. doi: 10.3389/fimmu.2021.619954

20. Bennoua J, Levy V, Sicard H, Senellart H, Audrain M, Hiret S, et al. Phase I Study of Bromohydrin Pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T Lymphocyte Activator. Cancer Immunol (2010) 59(1):1521–30. doi: 10.1002/cum.20879-07-8970

21. Tanaka Y, Kobayashi H, Terasaki T, Toma H, Aruga A, Uchiyama T, et al. Synthesis of Pyrophosphate-Containing Compounds That Stimulate Vγ9Vδ2 T Cells: Application to Cancer Immunotherapy. Med Chem (2007) 3(1):85–99. doi: 10.2174/157340607779317544

22. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Rudiger T, et al. T Cells for Immune Therapy of Patients With Lymphoid Malignancies. Blood (2003) 102:200–6. doi: 10.1182/blood-2002-12-3665

23. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, et al. Targeting Human γδ T Cells With Zoledronate and Interleukin-2 for Immunotherapy of Hormone-Refractory Prostate Cancer. Cancer Res (2007) 67(15):7450–7. doi: 10.1158/0008-5472.CAN-07-0199

24. Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, et al. Pilot Trial of Interleukin-2 and Zoledronic Acid to Augment γδ T Cells as Treatment for Patients With Refractory Renal Cell Carcinoma. Cancer Immunol Immunother (2011) 60(10):1447–60. doi: 10.1007/s00262-011-1049-8
Saura-Esteller et al.

47. Sakamoto M, Nakajima J, Murakawa T, Fukami T, Yoshida Y, Murayama T, Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, et al.

51. Aoki T, Matsushita H, Hoshikawa M, Hasegawa K, Kokudo N, Kakimi K.

53. Hoeres T, Smetak M, Pretscher D, Wilhelm M. Improving the Efficiency of VY962 T-Cell Immunotherapy in Cancer. *Front Immunol* (2018) 9:800. doi: 10.3389/fimmu.2018.00800

54. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H, et al. Successful Adoptive Transfer and *In Vivo* Expansion of Haploidentical GammaDelta T Cells. *J Transl Med* (2014) 12:45. doi: 10.1186/1479-5876-12-45

55. Lamb LSr., Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, et al. Increased Frequency of TCR Gamma Delta + T Cells in Disease-Free Survivors Following T Cell-Depleted, Partially Mismatched, Related Donor Bone Marrow Transplantation for Leukemia. *J Hematother* (1996) 5(5):503–9. doi: 10.1089/scd.1996.5.503

56. Godder KT, Henslee-Downey PJ, Mehta J, Park BS, Chiang KY, Abhyankar S, et al. Long Term Disease-Free Survival in Acute Leukemia Patients Recovering With Increased γδ T Cells After Partially Mismatched Related Donor Bone Marrow Transplantation. *Bone Marrow Transplantation* (2007) 39(12):751–7. doi: 10.1038/sj.bm.1705650

57. Lin M, Zhang X, Liang S, Luo H, Alnaggar M, Liu A, et al. Irreversible Electroporation Plus Allogeneic Vγ9Vδ2 T Cells Enhances Tumor Cell Lysis: A Pilot Study. *Cancer Immunol Immunother* (2007) 56(4):469–76. doi: 10.1007/s00262-006-0199-6

58. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philipp I, Galea C, et al. Phase-I Study of Innacell γδT, an Autologous Cell-Based Therapy Product Highly Enriched in γδ T Lymphocytes, in Combination With IL-2, in Patients With Metastatic Renal Cell Carcinoma. *Cancer Immunol Immunother* (2008) 57(11):1599–609. doi: 10.1007/s00262-008-0491-8

59. Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K. Phase II/III Study of Adoptive Transfer of γδ T Cells in Combination With Zoledronic Acid and IL-2 to Patients With Advanced Renal Cell Carcinoma. *Cancer Immunol Immunother* (2011) 60(8):1075–84. doi: 10.1007/s00262-011-1021-7

60. Mirzaei HR, Mirzaei H, Lee SY, Hadjati J, Till BG. Prospects for Chimeric Antigen Receptor (CAR) γδ T Cells: A Potential Game Changer for Adoptive T Cell Cancer Immunotherapy. *Cancer Letters* (2016) 380(2):413–23. doi: 10.1016/j.canlet.2016.07.001

61. Sadelain M, Riviere J, Riddell S. Therapeutic T Cell Engineering. *Nature* (2017) 545(7655):423–31. doi: 10.1038/nature22395

62. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delsbrook, C, Feldman SA, et al. T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-escalation Trial. *Lancet* (2015) 385(9967):579–80. doi: 10.1016/S0140-6736(14)64103-3

63. Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-Term Follow-Up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. *N Engl J Med* (2018) 378(3):449–59. doi: 10.1056/NEJMoa1710999

64. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-Refactory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies can be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor. *J Clin Oncol* (2015) 33(5):540–9. doi: 10.1200/JCO.2014.56.2025

65. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med* (2020) 382(14):1331–42. doi: 10.1056/NEJMoa1914377

66. Shuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGurk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med* (2019) 380(1):45–56. doi: 10.1056/NEJMoa1804980

67. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisoctagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study. *Lancet* (2020) 396(10254):839–52. doi: 10.1016/S0140-6736(20)31366-6

68. Sterne RC, Sterne RM. CAR-T-Cell Therapy: Current Limitations and Potential Strategies. *Blood Cancer J* (2021) 11(4):69. doi: 10.1038/s41408-021-01459-7
Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, Wallet M, Nishimura T, Del Casale C, Lebid A, Salantes B, Santostefano K, Siegers GM, Lamb LS Jr. Cytotoxic and Regulatory Properties of Circulating Vε T Cells With a Chimeric Antigen Receptor or an ε/β-J T-Cell Receptor: A Safer Alternative to Genetically Engineered ε/β T Cells for the Immunotherapy of Melanoma. *BMC Cancer* (2017) 17(1):551. doi: 10.1186/s12885-017-3539-9

Ang WX, Ng YY, Xiao L, Chen C, Li Z, Chi Z, et al. Electroporation of GPC-3-Specific Vδ1 Gamma Delta T Cells Engineered With Glypican-3 Cell Receptor: A Safer Alternative to Genetically Engineered Vδ1 T Cells for TARGETING OF Tissue-Resident Gamma Delta T Cells With Recombinant Single-Domain Antibody Boosts Autologous Vγ9Vδ2 T-Cell-Mediated Antitumor Immune Response. *Int J Mol Sci* (2021) 22(3):1373. doi: 10.3390/ijms22031373

Benyamine A, Loncle C, Foucher E, Blazquez JL, Castanier C, Chretien AS, et al. BTN3A Is a Prognosis Marker and a Promising Target for Gvagammas9Vδ Cells That Show CAR-T Cells Directed Against Autologous HER-2 Expressing High-Grade Ovarian Tumors. *Sci Rep* (2021) 11(1):608. doi: 10.1038/s41598-021-85632-8

Risser M, Pscherer S, Duwe S, Vormoor J, Jurgens H, Rossig C. Human Vδ+Vε T Cells Expressing Polyclonal Repertoire of Endogenous Gammadelta T Cells as Mediators of Chimaeric Receptor Redirected Anti-Tumour Immunity. *Br J Haematol* (2012) 164(4):583–92. doi: 10.1111/j.1365-2457.2009.07777.x

Harrer DC, Simon B, Fuji s-I, Shimizu K, Uda U, Schuler G, et al. RNA-Transfection of γδ T Cells With a Chimeric Antigen Receptor or an ε/β-J T-Cell Receptor: A Safer Alternative to Genetically Engineered ε/β T Cells for the Immunotherapy of Melanoma. *BMC Cancer* (2017) 17(1):551. doi: 10.1186/s12885-017-3539-9

Hisamoto T, Chen V, Dees S, Grewal IS. Overcoming the Challenges Associated With Cytotoxic and Regulatory Properties of Circulating Vδ T Cells With a Chimeric Antigen Receptor or an ε/β-J T-Cell Receptor: A Safer Alternative to Genetically Engineered ε/β T Cells for the Immunotherapy of Melanoma. *BMC Cancer* (2017) 17(1):551. doi: 10.1186/s12885-017-3539-9

Singh A, Dees S, Grewal IS. Overcoming the Challenges Associated With Cytotoxic and Regulatory Properties of Circulating Vδ T Cells With a Chimeric Antigen Receptor or an ε/β-J T-Cell Receptor: A Safer Alternative to Genetically Engineered ε/β T Cells for the Immunotherapy of Melanoma. *BMC Cancer* (2017) 17(1):551. doi: 10.1186/s12885-017-3539-9

Lambs I, Serafimides N, Santostefano K, Siegers GM, Lamb LS Jr. Cytotoxic and Regulatory Properties of Circulating Vε T Cells With a Chimeric Antigen Receptor or an ε/β-J T-Cell Receptor: A Safer Alternative to Genetically Engineered ε/β T Cells for the Immunotherapy of Melanoma. *BMC Cancer* (2017) 17(1):551. doi: 10.1186/s12885-017-3539-9

Ang WX, Ng YY, Xiao L, Chen C, Li Z, Chi Z, et al. Electroporation of GPC-3-Specific Vδ1 Gamma Delta T Cells Engineered With Glypican-3 Cell Receptor: A Safer Alternative to Genetically Engineered Vδ1 T Cells for TARGETING OF Tissue-Resident Gamma Delta T Cells With Recombinant Single-Domain Antibody Boosts Autologous Vγ9Vδ2 T-Cell-Mediated Antitumor Immune Response. *Int J Mol Sci* (2021) 22(3):1373. doi: 10.3390/ijms22031373

Benyamine A, Loncle C, Foucher E, Blazquez JL, Castanier C, Chretien AS, et al. BTN3A Is a Prognosis Marker and a Promising Target for Gvagammas9Vδ Cells That Show CAR-T Cells Directed Against Autologous HER-2 Expressing High-Grade Ovarian Tumors. *Sci Rep* (2021) 11(1):608. doi: 10.1038/s41598-021-85632-8

Risser M, Pscherer S, Duwe S, Vormoor J, Jurgens H, Rossig C. Human Vδ+Vε T Cells Expressing Polyclonal Repertoire of Endogenous Gammadelta T Cells as Mediators of Chimaeric Receptor Redirected Anti-Tumour Immunity. *Br J Haematol* (2012) 164(4):583–92. doi: 10.1111/j.1365-2457.2009.07777.x

Harrer DC, Simon B, Fuji s-I, Shimizu K, Uda U, Schuler G, et al. RNA-Transfection of γδ T Cells With a Chimeric Antigen Receptor or an ε/β-J T-Cell Receptor: A Safer Alternative to Genetically Engineered ε/β T Cells for the Immunotherapy of Melanoma. *BMC Cancer* (2017) 17(1):551. doi: 10.1186/s12885-017-3539-9

Hisamoto T, Chen V, Dees S, Grewal IS. Overcoming the Challenges Associated With Cytotoxic and Regulatory Properties of Circulating Vδ T Cells With a Chimeric Antigen Receptor or an ε/β-J T-Cell Receptor: A Safer Alternative to Genetically Engineered ε/β T Cells for the Immunotherapy of Melanoma. *BMC Cancer* (2017) 17(1):551. doi: 10.1186/s12885-017-3539-9
and Temozolomide Chemotherapy Is Effective Against Primary High Grade Gliomas. Sci Rep (2021) 11(1):21133. doi: 10.1038/s41598-021-00536-8

107. Lamb LS, Bowersock J, Dasgupta A, Gillespie GY, Su Y, Johnson A, et al. Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines During a Chemotherapy Challenge: A Strategy for Combining Chemo- and Immunotherapy. PLoS One (2013) 8(1):e51805. doi: 10.1371/journal.pone.0051805

108. van Diest E, Hernandez Lopez P, Meringa AD, Vyborova A, Karaiskaki F, Heijhuurs S, et al. Gamma Delta TCR Anti-CD3 Bispecific Molecules (GABs) as Novel Immunotherapeutic Compounds. J Immunother Cancer (2021) 9(11):e003850. doi: 10.1136/jitc-2021-003850

109. Barber A, Wang X, Gopisetty A, Mirandola L, Chiriva-Internati M. Abstract LB148: Gamma Delta T Cells Engineered With a Chimeric PD-1 Receptor Effectively Control PD-L1 Positive Tumors In Vitro and In Vivo With Minimal Toxicities. Cancer Res (2021) #1Supplement):LB148–LB. doi: 10.1158/1538-7445.AM2021-LB148

Conflict of Interest: JS-E, MJ and LK are funded by Lava therapeutics. HV, PP, EE, BW are employed by and hold stock of LAVA Therapeutics. TG holds stock of LAVA Therapeutics.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Saura-Esteller, de Jong, King, Ensing, Winograd, de Gruijl, Parren and van der Vliet. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.